Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLGN 
Collplant Biotechnologies Ltd (CLGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CLGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.56
1 Year Target Price $11.56
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.35% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.82M USD | Price to earnings Ratio - | 1Y Target Price 11.56 |
Price to earnings Ratio - | 1Y Target Price 11.56 | ||
Volume (30-day avg) 1 | Beta 0.81 | 52 Weeks Range 1.31 - 5.00 | Updated Date 09/16/2025 |
52 Weeks Range 1.31 - 5.00 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-20 | When - | Estimate -0.14 | Actual 0.23 |
Profitability
Profit Margin - | Operating Margin (TTM) -1775.42% |
Management Effectiveness
Return on Assets (TTM) -37.9% | Return on Equity (TTM) -78.25% |
Valuation
Trailing PE - | Forward PE 15.55 | Enterprise Value 25036116 | Price to Sales(TTM) 13.66 |
Enterprise Value 25036116 | Price to Sales(TTM) 13.66 | ||
Enterprise Value to Revenue 10.42 | Enterprise Value to EBITDA -5.97 | Shares Outstanding 12716000 | Shares Floating 8913163 |
Shares Outstanding 12716000 | Shares Floating 8913163 | ||
Percent Insiders 10.16 | Percent Institutions 12.23 |
Upturn AI SWOT
Collplant Biotechnologies Ltd
Company Overview
History and Background
Collplant Biotechnologies Ltd. was founded in 2004, focusing on recombinant human collagen (rhCollagen) production using plants. Initially focused on tissue repair, it evolved to include medical aesthetics and regenerative medicine applications.
Core Business Areas
- Bioprinting and 3D Printing: Focuses on using rhCollagen in 3D printing applications for regenerative medicine, including developing bioinks and implants for organ and tissue repair.
- Regenerative and Aesthetic Medicine: Develops and manufactures rhCollagen-based products for tissue repair, orthobiologics, and aesthetics. This includes products aimed at improved healing and tissue regeneration.
Leadership and Structure
Yehiel Tal is the CEO. The company operates with a scientific advisory board and a management team spanning research, development, and commercialization functions.
Top Products and Market Share
Key Offerings
- VerteOss: A bone void filler composed of rhCollagen and beta-tricalcium phosphate (u03b2-TCP). Used in orthopedic procedures to promote bone regeneration. Competitors include Medtronic (MDT) Infuse, Stryker (SYK) bone graft substitutes. Market share is relatively small compared to larger players. Revenue is still not significant.
- rhCollagen-based Bioink: Bioink designed for 3D bioprinting of tissues and organs. Aimed at research and eventual clinical applications. Competitors include BICO (BICO.ST) and CELLINK. Revenue is still in development and exploratory phase.
Market Dynamics
Industry Overview
The regenerative medicine industry is experiencing substantial growth, driven by advancements in biotechnology and increasing demand for minimally invasive treatments. 3D bioprinting is an emerging field with significant potential.
Positioning
Collplant is positioned as an innovator in the rhCollagen field, focusing on its unique production capabilities. They aim to be a key supplier in both the regenerative medicine and 3D bioprinting markets.
Total Addressable Market (TAM)
The global regenerative medicine market is projected to reach hundreds of billions of USD within the next decade. Collplant is positioned to capture a share of this TAM through its rhCollagen technology, aiming for strategic partnerships and expanding product applications.
Upturn SWOT Analysis
Strengths
- Proprietary rhCollagen technology
- Strong intellectual property portfolio
- Potential for strategic partnerships
- Focus on innovative regenerative medicine applications
Weaknesses
- Limited commercialized product portfolio
- Dependence on strategic partners for market access
- Relatively small revenue base
- High research and development expenses
Opportunities
- Expanding into new regenerative medicine markets
- Securing additional strategic partnerships
- Developing new rhCollagen-based products
- Increased adoption of 3D bioprinting technology
Threats
- Competition from larger, established companies
- Regulatory hurdles
- Technological advancements by competitors
- Market acceptance of novel regenerative medicine products
Competitors and Market Share
Key Competitors
- MDT
- SYK
- BICO.ST
- CELLINK
Competitive Landscape
Collplant benefits from its proprietary rhCollagen but faces the challenge of competing with larger firms that possess vast resources and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been sporadic, with surges depending on partnership deals and research outcomes.
Future Projections: Future growth relies on the success of its clinical trials and partnership agreements. Analyst projections vary widely due to the speculative nature of the company.
Recent Initiatives: Recent initiatives include expanding partnerships in bioprinting, orthopedic, and aesthetics applications.
Summary
Collplant Biotechnologies is a company that has developed a proprietary rhCollagen technology with potential uses in several markets, including regenerative medicine and 3D bioprinting. The company has strong intellectual property and is focused on innovation, but it must compete with bigger companies. Revenue is volatile, and the company relies on strategic partnerships to access the market. Therefore, the company's success rests upon positive clinical trials, product commercialization, and additional funding to pursue its goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate and may vary. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collplant Biotechnologies Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-01-30 | CEO & Director Mr. Yehiel Tal | ||
Sector Healthcare | Industry Biotechnology | Full time employees 57 | Website https://collplant.com |
Full time employees 57 | Website https://collplant.com | ||
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel for the treatment of chronic and acute wounds. The company also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.